Landscape Of Glaucoma Competition 2023: 45+ Firms, 50+ Drugs

There is a report on Glaucoma available. It is called "Glaucoma - Competitive Landscape, 2023". You can find it on ResearchAndMarkets.com.

This report gives information about 45+ companies and 50+ drugs in the Glaucoma Competitive landscape. It talks about the types of products, how developed they are, how they are given, and what they are made of. The report also talks about products that are not being developed anymore.

Glaucoma is when the optic disc gets cupped and you can't see well due to losing cells. It's bad because it gets worse over time and can make you blind. There are two types: open-angle and narrow-angle or angle-closure. Both have to do with how water flows through your eye.

The most common type of glaucoma is open-angle glaucoma. Your eye's drainage angle stays open but gets partly blocked. This causes pressure in your eye and hurts your optic nerve.

Glaucoma can sneak up on you. Sometimes, you won't notice you have a problem until you start to lose your vision. Narrow-angle glaucoma is when the drainage angle inside your eye gets blocked. This can cause pressure to build up and could lead to vision loss. If the angle is completely blocked, it's called angle-closure glaucoma.

Glaucoma often has no early symptoms. Blind spots can happen in peripheral vision as the disease damages optic nerve fibers. People may not notice the blind spots until too late. Total blindness can occur if the nerve is destroyed.

Early-stage glaucoma often goes undetected because there are no symptoms. By the time it's detected, it has advanced considerably. People used to think that it only affected peripheral vision. Central vision was believed to be safe until the disease was very advanced.

New research proves that losing peripheral vision is not always the first sign of glaucoma. Both central and peripheral vision can be affected. The current test for peripheral vision is not accurate enough to detect early vision loss. Sadly many patients only find out about their glaucoma after losing half of their optic nerve fibers. Scientists are working on better ways to catch glaucoma earlier by developing more precise tests for central vision.

Glaucoma is a disease that you can get from your family. If your family has it, you might get it too. Other things can make it more likely for you to get glaucoma. These things include having thin parts of your eyes, having certain health problems like diabetes or being very overweight, and other eye problems.

Glaucoma has no cure. But doctors can prevent damage and protect eyesight through early treatment. Treatments for glaucoma include eye drops, laser therapy, and surgery.

Visiox Pharma got news from the US FDA in Dec 2022. The FDA finished their review of their drug, PDP-716. PDP-716 is made to treat glaucoma. The FDA agreed to file a New Drug Application for PDP-716.

In October 2022, Essex Biotechnology Ltd shared that its subsidiary, Essex Bioinvestment Ltd, got hold of a license agreement and a patent deed for SkQ1 from Mitotech S.A. The agreements grant Essex Bioinvestment rights to SkQ1 for ophthalmology worldwide, except in a few countries.

Santen Pharmaceutical said EMA accepted their filing for review. They want to use STN1013001 to lower IOP in open-angle glaucoma and ocular hypertension. The application is based on a Phase III clinical trial with good results from Europe and Asia. It was a non-inferiority trial.

TearClear said its main product, TC-002, passed all trials. This happened in September 2022. TearClear will ask the FDA to approve TC-002 in 2023.

Qlaris Bio shared news on QC-201, their clinical trial for QLS-101, in May 2022. This is their experimental treatment for lowering intraocular pressure (IOP) to treat glaucoma. The trial showed a positive result, indicating that QLS-101 was safe and well-tolerated without hyperemia. Patients experiencing primary open-angle glaucoma (POAG) or ocular hypertension benefited from the treatment’s positive efficacy signal.

Sun Pharma Advanced Research made a deal with Visiox Pharma. They granted exclusive rights worldwide (except India and Greater China) to develop and sell PDP-716 and SDN-037. As part of the agreement, SPARC got an upfront payment, milestone payments, and royalties. They also got 10% equity in Visiox.

The current ways of treating diseases and disorders aren't perfect. But there are new treatments being developed that could help people feel better. These new therapies are still being tested and studied, so we don't know how effective they'll be. But experts are hopeful that they'll make a big difference. These emerging therapies range from new drugs to different ways of delivering existing treatments. So even if current treatments don't work for everyone, there's hope that something else will.

There are several firms working on drugs for Glaucoma treatment.

Every company develops different amounts of drugs for Glaucoma.

There are a lot of drugs being developed for Glaucoma. Some are in mid-stage development and some are in late-stage development. How many exactly? We don't know.

What collaborations are happening in the Glaucoma therapeutics industry? Who is joining forces with academia or other companies? Are there any mergers or acquisitions occurring? What about licensing deals?

What new things are happening in the world of medical treatments? What are the new drugs being created? What are the latest technologies being used to improve existing therapies?

What research is being done for Glaucoma? And how is it going?

Which are the important titles awarded to new and authorized medications? FDA gives approval or emergency use authorization (EUA) to novel drugs. After its completion of clinical trials, the new drug gets FDA approval. EUA is granted in case the drug's benefits outweigh its risks. FDA also identifies "Breakthrough Therapy" and "Fast Track" designations for some emerging drugs. "Breakthrough Therapy" is approved to the drug showing potential for significant advancement in its treatment of diseases. "Fast Track" is for drugs that can satisfy unmet clinical needs and reach patients faster. These designations are beneficial to manufacturers in every phase of drug advancement.

Want more details? Check out the report at https://www.researchandmarkets.com/r/ur4rd9.

ResearchAndMarkets.com is the top source for global market research reports and data. Our reports cover international & regional markets, industries, top companies, new products, and the latest trends.